The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Simply sign up to the War in Ukraine myFT Digest -- delivered directly to your inbox. Brussels is proposing a ban on video game equipment sales to Russia to stop the country’s armed forces using ...

But hidden at your pharmacy among the potpourri of cough drops and cold remedies, you can find a low-risk treatment that actually may help: nasal irrigation devices. Several small studies suggest ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The FDA’s latest approval of the nasal spray Spravato (esketamine ... Clinical trials are underway or being planned to test esketamine in postpartum depression, risk of suicide, sleep ...

In a first for world football, Manchester City will showcase a bespoke goalkeeper kit designed by City stars using generative AI on-pitch this weekend. One of these fan-designed kits will become our ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

A nasal rinse is a common practice to clear nasal passages, especially during cold, flu, and allergy seasons. It helps remove mucus, debris, and allergens that build in the nose. “A saltwater rinse is ...

The Sims 4 will be getting two new Creator Kits on January 30th: Refined Living Room and Business Chic. Refined Living Room will be a Build Kit adding modern and stylish furniture, while Business Chic ...

Amid fresh controversy over the Board of Control for Cricket in India's alleged refusal to have 'Pakistan' printed on the team's Champions Trophy kits as part of the tournament logo, the Indian ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...